TY - JOUR
AU - Volc‐Platzer, B.
AB - Research letters 165 Our results suggest that IRF4 rs12203592 is associated with international study of primary melanomas. Br J Dermatol 2017; 177: e1802. poorer melanoma-specific survival, largely mediated through 2 Potrony M, Rebollo-Morell A, Gim
enez-Xavier P et al. IRF4 Breslow thickness, reinforcing our previous findings related to rs12203592 functional variant and melanoma survival. Int J Cancer rs12203592*T and tumour thickness. This variant’s adverse 2017; 140:1845–9. effect on survival may occur through its functional effect on 3 Begg C, Hummer A, Mujumdar U et al. A design for cancer case– IRF4 expression. The SNP is known to modulate IRF4 enhan- control studies using only incident case: experience with the GEM cer-mediated transcriptional regulation in melanocytes, and it study of melanoma. Int J Epidemiol 2006; 35:756–64. 4 Ward S, Cadby G, Lee A et al. The Western Australian Melanoma may play a similar role in immune cells. Increased IRF4 Health Study: study design and participant characteristics. Cancer Epi- expression in immune cells and the subsequent activation of demiol 2011; 35:423–31. the TERT promoter has been shown to increase telomerase 5 Fine JP, Gray RJ. A proportional hazards model for the subdistribu- activity, which in turn has been associated with increased tion 
TI - Successful treatment of Netherton syndrome with ustekinumab in a 15‐year‐old girl
JO - British Journal of Dermatology
DO - 10.1111/bjd.18892
DA - 2020-07-01
UR - https://www.deepdyve.com/lp/oxford-university-press/successful-treatment-of-netherton-syndrome-with-ustekinumab-in-a-15-OXKd5oKOPI
SP - 165
EP - 167
VL - 183
IS - 1
DP - DeepDyve
ER -